Neurosteroid enantiomer

Phase 2Small molecule

OOragenics, Inc.

Neurosteroid enantiomer is one of 42 small molecule programs targeting Brain Injury. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain InjuryActive, not recruiting

Brain InjuryPhase 2

Active, not recruiting

Competition

Competitive Landscape

245 competitors in Brain Injury

#DrugCompanyPhaseTrials

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 2

Brintellix

Takeda

Phase 3

1 3

Zyloprim

Alnylam Pharmaceuticals

Phase 3

1 4

Epsom Salt

FFresenius Kabi Oncology Ltd.

Phase 3

5 5

Cyklokapron

AAmring

Phase 3

4 6

Prometrium

Ferring

Phase 3

2 7

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

2 8

Nuvigil

NNuvo Research GmbH

Phase 3

2 9

Rocephin

CConrado Roberto Hoffmann Filho

Phase 3

1 10

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Brain Injury1 trial

A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury

Not yet recruiting·OOragenics, Inc.·Phase 2·NCT06870240·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Neurosteroid enantiomer. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neurosteroid enantiomer compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neurosteroid enantiomer. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oragenics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOragenics, Inc.

Neurosteroid enantiomer

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Brain Injury1 trial

References

Drug Info

Quick Facts

Related News